See Patricia Van Arnum's bio page.
Patricia Van Arnhum reviews 2013's crop of the new molecular entities and new biologics license applications approved by FDA.
The pharma majors are targeting biologics and emerging markets in their manufacturing expansion activities and plans. Patricia Van Arnum reports.
The US and EU move forward with measures to fortify the pharmaceutical supply chain, writes Patricia Van Arnum.
The problem of supply-chain security has taken center stage with a number of recent initiatives, writes Patricia Van Arnum.
As pharma increases its level of outsourcing, its models for partnering are evolving. The highly collaborative preferred-provider relationships, for example.
Supply Chain Strategy: Managing risk and opportunity in a changing global landscape
Sponsored By PricewaterhouseCoopers LLP Optimizing the Multi-Sponsor REMS Experience (Risk Evaluation & Mitigation Strategies)
Sponsored By PricewaterhouseCoopers LLP Effective Resource Planning: Reducing Clinical Project Risk and Operating Cost
Sponsored By ClearTrial